Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: CSSE Johns Hopkins University; Map: Andrew Witherspoon/Axios

The pace of new coronavirus infections in the U.S. fell by nearly 20% over the past week — the fifth straight week of double-digit declines.

The big picture: America’s vaccination drive is working, and as it continues to expand, the country can safely get back to many of its pre-pandemic routines.

By the numbers: The U.S. averaged roughly 24,000 new cases per day over the past week, a 20% drop from week before. Cases have fallen every week since mid-April.

  • 38 states improved over the past week. Only four states saw their outbreaks grow.
  • This is happening because of the vaccines. Half of American adults are fully vaccinated, and roughly 62% of adults have gotten at least one shot, according to the CDC.

What’s next: The pandemic continues to rage overseas, and the Biden administration will face increasing pressure to export more vaccines now that the virus is so well contained in the U.S.

Each week, Axios tracks the change in new infections in each state. We use a seven-day average to minimize the effects of day-to-day discrepancies in states’ reporting.

Go deeper

Updated 4 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Brendan Lynch/Axios

  1. Health: The disproportionate impact of COVID-19 on young Hispanic Americans — Emergency room visits of all kinds dropped amid the pandemic — NY smart-thermometer network could predict next COVID wave.
  2. Vaccines: Vermont becomes first state to reach 80% vaccine thresholdNovavax says COVID-19 vaccine was 90% effective in Phase 3 trial — FDA clears 10 million J&J vaccine doses from contaminated Baltimore plant.
  3. Politics: U.S. to buy 500 million Pfizer doses to share with the world — State Department eases travel advisories for dozens of countries.
  4. Cities: New York City to host ticker tape parade for essential workers
  5. World: The G7's billion-dose pledge, heralded by Biden, doesn't add up — Boris Johnson extends England's COVID restrictions to curb variant spreadMoscow orders new restrictions amid surge in COVID-19 cases.
  6. 🎧 Podcast: Back to normal without herd immunity.
  7. Variant tracker: Where different strains are spreading.
May 26, 2021 - Health

New York will raffle off scholarships to kids who get vaccinated

New York Gov. Andrew Cuomo at a press conference on May 11. Photo: Michael M. Santiago/Getty Images

New York will raffle off 50 four-year scholarships to any public college or university in the state for people between 12–17 years old who receive a coronavirus vaccine from tomorrow until July 7, New York Gov. Andrew Cuomo announced Wednesday.

Why it matters: It's part of the state's initiative to vaccinate young people after the Centers for Disease Control and Prevention approved the use of Pfizer-BioNTech's coronavirus vaccine in 12- to 15-year-olds.

May 26, 2021 - Health

FDA authorizes third COVID antibody therapy treatment

A GlaxoSmithKline factory. Photo: Kenzo Tribouillard/AFP via Getty Images

The U.S. Food and Drugs Administration on Wednesday authorized Vir Biotechnology and GlaxoSmithKline's monoclonal antibody drug treatment for early COVID infections, the agency said.

Why it matters: It's the third antibody treatment authorized for patients in the early stages of the disease who are at high risk of developing severe infections. The drug is "expected" to protect against variants, according to the FDA.